Why Is Hims & Hers Health Stock Trading Lower On Wednesday?
1. HIMS stock down 5.98% with lower trading volume than average. 2. Novo Nordisk launched NovoCare Pharmacy, reducing Wegovy prices for cash patients. 3. Hims reported Q4 revenue of $481.14 million, exceeding estimates. 4. The stock dropped 20% after semaglutide injections were removed from shortage list. 5. Hims is reliant on GLP-1 revenue exceeding $225 million in 2024.